- Stocks
- Healthcare
ICCM
IceCure Medical Ltd
ICCM
NASDAQ·Healthcare·Medical - Devices·Mkt cap $5.0M
$2.23
▲ +1.36%
P/E
-1.36
Mkt Cap
$5.0M
52-Wk Range
$2.12–$42.00
52-Week Range
$2.12 - $42.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 92.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cryoablation technology
- Minimally invasive treatment approach
- Strong intellectual property portfolio
- Established regulatory approvals and clinical evidence
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Expansion into additional cancer indications beyond breast tumors
Value
Valuation data unavailable
Momentum
Falling
-38.7% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ICCM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 12, 2026
Reported EPS of -$1.54 vs -$1.52 consensus (-1.3% surprise). Revenue of $907.0K vs $1.5M expected (-37.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.3%
Revenue trend · last 8Q
—
—
-2%
-48%
+28%
+46%
+26%
+73%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$662.0K
$875.0K
$725.0K
$525.0K
$850.0K
$1.3M
$911.0K
$907.0K
Margins · last 8Q
Gross
27.9%
Profit
-496.3%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Maxim Group · May 14, 2026
vs Industry
How ICCM stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related